C

cAMPfield Therapeutics

Develops oral PDE4 inhibitors for IBD

Senior Director, Translational Medicine - Translational Medicine

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeBoston, MA, USANo salary listed

About the Job

Requirements

  • A PhD, MD, or MD/PhD in immunology, pharmacology, gastroenterology, or a related field.
  • At least 12 years of translational medicine or translational research experience in biotech or pharma, including direct experience in immune-mediated inflammatory disease.
  • A demonstrated track record of designing and executing biomarker strategies that influenced clinical development decisions, such as dose selection, go/no-go decisions, or patient stratification.
  • A strong publication record and experience representing translational science externally to key opinion leaders, regulators, and scientific conferences.
  • Demonstrated leadership experience building or managing a translational medicine or biomarker function.
  • Strong cross-functional collaboration skills and comfort operating in a lean, fast-moving biotech environment.

Responsibilities

  • Define and lead the translational medicine strategy across the prifemilast clinical program, from Phase 2 through registration-enabling studies.
  • Design biomarker, pharmacodynamic, endoscopic, and histopathology sample strategies that link target engagement and mechanism of action to clinical response in inflammatory bowel disease.
  • Partner with Clinical Development, Clinical Pharmacology, and Biostatistics to integrate translational endpoints into protocol design and data analysis plans.
  • Identify and validate biomarkers of disease activity, mucosal healing, and treatment response; explore predictive biomarkers to support patient stratification.
  • Evaluate and manage relationships with central reading, histopathology, bioanalytical, and companion diagnostic vendors and academic collaborators.
  • Translate emerging preclinical and clinical biomarker data into actionable recommendations for program strategy, including dose selection and lifecycle opportunities.
  • Represent translational medicine in regulatory interactions and health authority briefing documents.
  • Contribute to scientific publications, congress presentations, and investor and board materials describing prifemilast's mechanism and differentiation.
  • Build and mentor a translational medicine function as the organization grows.

Desired Qualifications

  • Inflammatory bowel disease experience is strongly preferred.
  • Deep understanding of gastrointestinal mucosal immunology and/or PDE4/cAMP signaling biology is a strong plus.
  • Experience working with endoscopic and histologic endpoints in inflammatory bowel disease trials is preferred.

About the Company

cAMPfield Therapeutics

Develops oral PDE4 inhibitors for IBD

cAMPfield Therapeutics develops oral small-molecule therapies for inflammatory and immunological diseases. Its lead program, prifemilast, is an oral PDE4 inhibitor being developed for inflammatory bowel disease (IBD), including ulcerative colitis. The drug’s mechanism targets PDE4 to reduce inflammation, and prifemilast has shown efficacy in Phase 2 studies for ulcerative colitis. The company focuses on in-licensing assets with potential to transform patient care and aims to establish prifemilast as a preferred IBD treatment with a favorable safety profile. Global rights to prifemilast (also known as HPP737) were acquired from vTv Therapeutics and Newsoara Biopharma. cAMPfield recently launched with a $180 million Series A led by top-tier investors, signaling growth plans and potential partnerships. The company’s goal is to bring a best-in-class oral PDE4 inhibitor to patients and pursue collaborations that advance its clinical programs.

Company size
11-50
Company stage
Series A
Total funding
$180M
Headquarters
San Diego, CA
Founded
2026

Recently Posted Jobs

Explore more opportunities at cAMPfield Therapeutics

See more jobs